Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | HTR2C | P28335 | 6/20 | 0.40 |
| ▸ | FLT3 | P36888 | 4/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198328 | 0.97 | FLT3 (0.41) | MAPK14RETHTR2AHTR2CFLT3 | |
| SCHEMBL3209349 | 0.94 | MAPK14 (0.43) | MAPK14RETHTR2AHTR2CFLT3 | |
| SCHEMBL3218578 | 0.94 | MAPK14 (0.42) | MAPK14HTR2AHTR2CFLT3 | |
| SCHEMBL3208082 | 0.94 | MAPK14 (0.42) | MAPK14HTR2AHTR2CFLT3KIT | |
| SCHEMBL3206182 | 0.93 | MAPK14 (0.45) | MAPK14RETHTR2AHTR2C | |
| SCHEMBL13495446 | 0.91 | FLT3 (0.41) | MAPK14RETHTR2AHTR2CFLT3 | |
| SCHEMBL3206302 | 0.91 | MAPK14 (0.43) | MAPK14RETHTR2AHTR2CFLT3 | |
| SCHEMBL3213052 | 0.91 | MAPK14 (0.42) | MAPK14FLT3KDR | |
| SCHEMBL3210187 | 0.89 | MAPK14 (0.43) | MAPK14RETFLT3 | |
| SCHEMBL3195773 | 0.89 | MAPK14 (0.43) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010019930-A1 | UREA DERIVATIVES AS INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | claimed |
| WO-2010019930-A1 | UREA DERIVATIVES AS INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | MAPK14 33/4885RET 1159/4885HTR2A 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.